RecruitingNCT05964504
Improving Survival for Metastatic Lobular Breast Cancer (PLUMB Registry)
Improving Survival for Those With Metastatic Lobular Breast Cancer Through Development of the Multi-center PLUMB Registry-a Prospective Study of LobUlar Metastatic Breast Cancer
Sponsor
University of California, San Francisco
Enrollment
12 participants
Start Date
Dec 20, 2023
Study Type
OBSERVATIONAL
Conditions
Summary
This is a prospective observational registry for patients with invasive lobular carcinoma (ILC) of the breast. After the first 1cohort is enrolled, the collected data will be utilized to develop an ILC specific response assessment tool.
Eligibility
Min Age: 18 Years
Inclusion Criteria4
- Histologically confirmed invasive lobular carcinoma. Mixed lobular/ductal cancer is allowed.
- Age \>=18 years
- Any receptor subtype.
- Ability to understand a written informed consent document, and the willingness to sign it.
Exclusion Criteria3
- Stage I-III breast cancer.
- Lack of lobular histology on tumor biopsy.
- Other active cancer (prior treated cancer with no current evidence of disease is allowed).
Interventions
PROCEDUREBlood Specimen
Blood will be drawn via venipuncture
Locations(4)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05964504
Related Trials
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
NCT06157892139 locations
Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer
NCT066493311 location
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
NCT0342400545 locations
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
NCT0708576735 locations
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
NCT06016738233 locations